Management of Elevated Estradiol in Men

Initial Assessment and Referral

Men with elevated baseline estradiol should be referred to an endocrinologist for evaluation and management, according to the American Urological Association (AUA) 1
The AUA recommends measuring serum estradiol in testosterone-deficient men who present with breast symptoms or gynecomastia prior to starting testosterone therapy 1
Any man found to have elevated baseline estradiol measurements requires endocrinology referral, regardless of whether testosterone therapy is being considered 1

The American Urological Association (AUA) suggests measuring luteinizing hormone (LH) levels in all men with hormonal abnormalities to determine if the issue is primary (testicular) or secondary (hypothalamic-pituitary) 1, 2
Men with low testosterone AND low/normal LH may be candidates for selective estrogen receptor modulator (SERM) therapy, particularly if fertility preservation is desired, as recommended by the AUA 1, 2, 3
The AUA recommends checking prolactin levels if LH is low or low-normal, as hyperprolactinemia can cause hormonal imbalances 1, 2

The American Heart Association recommends lifestyle modifications, including smoking cessation, regular dynamic exercise, weight loss, Mediterranean diet, and moderate alcohol consumption, to decrease estradiol levels and increase testosterone levels 4, 5, 6

The European Association of Urology notes that breast cancer growth is influenced by testosterone conversion to estradiol, making active or treated male breast cancer an absolute contraindication to testosterone therapy 7
The American Urological Association (AUA) advises against attempting to manage elevated estradiol without specialist input, as the underlying cause must be identified first 1

Anastrozole should NOT be used as monotherapy in men with hypogonadotropic hypogonadism, as these men may benefit from selective estrogen receptor modulators (SERMs) or gonadotropin therapy instead, as recommended by The Journal of Urology 8
Anastrozole should NOT be used as monotherapy in men with fertility concerns, as aromatase inhibitors alone may not preserve fertility; SERMs or gonadotropin therapy are preferred, according to The Journal of Urology 8
For the rare case of male breast cancer patients requiring estradiol suppression, GnRH agonist/antagonist PLUS aromatase inhibitor is the recommended combination, as aromatase inhibitors alone may not achieve complete estradiol suppression in men, as stated in the Journal of Clinical Oncology 9
Tamoxifen is contraindicated if the goal is to lower estradiol levels, as it blocks estrogen receptors but does not reduce circulating estradiol, as reported in the Journal of Clinical Oncology 9
Testosterone monotherapy should not be used in men interested in fertility, as it suppresses spermatogenesis, according to The Journal of Urology 8

The American College of Clinical Endocrinologists recommends that men with active or treated breast cancer should not use testosterone or androgen supplementation, as testosterone aromatizes to estradiol and can stimulate estrogen receptor-positive cancer cells, causing recurrence or progression 10
The American Society of Clinical Oncology suggests that assessing for underlying malignancy, particularly estrogen receptor-positive breast cancer, is crucial in men with elevated estradiol, as it requires specific management protocols 10

The Endocrine Society recommends that men with hormone-sensitive malignancies should use GnRH agonist/antagonist PLUS aromatase inhibitor (anastrozole or letrozole) to achieve complete estradiol suppression 10
The European Association of Urology suggests that men with hypogonadotropic hypogonadism and high estradiol should not use anastrozole as monotherapy, as these men benefit from SERMs or gonadotropin therapy instead 10

The American Heart Association notes that high estradiol levels are associated with increased all-cause mortality, non-cardiovascular mortality, and cancer mortality in older men 10
The European Society of Cardiology suggests that high estradiol levels are associated with a higher prevalence of stroke, peripheral vascular disease, and carotid stenosis 10